Renal Cell Carcinoma – Talk Bio

Actionable Insights Powered by AI

ESMO 2023: Merck’s Welireg Demonstrates Sustained PFS Benefit in Advanced Renal Cell Carcinoma, Despite Ongoing OS Concerns

9 months ago talkbio0Tagged belzutifan, Co., ESMO, LITESPARK-005 trial, Overall Survival, Progression-Free Survival, Renal Cell Carcinoma, Welireg

Merck & Co., Welireg (belzutifan), ESMO 2023, Advanced Renal Cell Carcinoma (RCC), Progression-Free Survival (PFS), Overall Survival (OS), LITESPARK-005 trial

AVEO Oncology’s Fotivda Combo Fails to Meet Primary Endpoint in Phase III Renal Cell Carcinoma Study

11 months ago talkbio0Tagged AVEO, Fotivda, Malignant neoplasm of kidney, Neoplasms, nivolumab, Phase 3 Clinical Trials, Renal Cell Carcinoma, tivozanib

AVEO Oncology, Fotivda, tivozanib, renal cell carcinoma, Phase III clinical trial, TiNivo-2 study, nivolumab, Opdivo, kidney cancer